CGONCG Oncology, Inc.

Nasdaq cgoncology.com


$ 31.46 $ -0.68 (-2.12 %)    

Friday, 21-Jun-2024 15:59:48 EDT
QQQ $ 479.17 $ 0.00 (0 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 31.43
$ 31.99
$ 0.00 x 0
$ 0.00 x 0
$ 31.09 - $ 32.85
$ 25.77 - $ 50.23
2,023,896
na
nm
$ 3.07
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price tar...

Core News & Articles

Goldman Sachs analyst Corinne Johnson upgrades CG Oncology (NASDAQ:CGON) from Neutral to Buy and raises the price target fro...

Core News & Articles

Goldman Sachs analyst Corinne Johnson upgrades CG Oncology (NASDAQ:CGON) from Neutral to Buy and announces $50 price target.

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price tar...

Core News & Articles

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.36) per share. This is a 88.82 percent increase over losses of $(3.2...

Core News & Articles

Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price tar...

Core News & Articles

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolyt...

Core News & Articles

Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.

Core News & Articles

CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a po...

Core News & Articles

HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price tar...

Core News & Articles

- PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology's earliest disease stage clinical trial for ...

Core News & Articles

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on CG Oncology (NASDAQ:CGON) with a Overweight rating and announc...